Biomarkers: Improving survival prediction for melanoma
The survival of patients with cutaneous melanoma can be accurately predicted using just four DNA methylation marks.
- Massachusetts General Hospital, United States
- Broad Institute, United States
Predicting the risk of outcomes in patients with cancer has traditionally relied on clinical observations: the age of the patient, the size of the tumor, how far it spreads, and how the tumor cells look under the microscope. The accuracy of these clinical evaluations depends on the type of cancer: this approach usually delivers good predictions for cancers that do not spread, but once the cancer metastasizes, the predictive power of this approach declines rapidly.
One of the most challenging cancers to make predictions for is cutaneous melanoma because it progresses rapidly and often spreads into the lymph nodes and other distant organs (Homsi et al., 2005). Cutaneous melanoma is the deadliest skin cancer (Miller and Mihm, 2006), so it is important to be able to manage patient expectations. This means that we need methods other than those based on clinical observations that can predict patient survival.
One alternative approach is based on biomarkers – biological properties within tumors that are associated with melanoma survival. For instance, research showed that several drugs for the treatment of melanoma only targeted tumors that carried a specific mutation in the BRAF gene: the presence of this mutation in a patient is therefore associated with a higher chance of survival due to a positive drug response (Figure 1). Indeed, subsequent research has shown that the higher the mutational 'burden' in the melanoma, the better the response to treatment (Goodman et al., 2017; Figure 1). The interaction between the transcription of genes in the tumor and the immune system is also important: depending on the melanoma tumor type, low levels of transcription of a gene called MITF results in fewer immune cells being attracted to the tumor, which leads to an acceleration in tumor growth (Wiedemann et al., 2019). Taken together, these findings highlight that understanding the biological characteristics of melanoma tumors is critical for predicting outcomes and developing new treatments.
Figure 1
Different ways to predict survival rates for patients with melanoma.
Some patients with a given cancer have higher survival rates than other patients with the same type of cancer: the discovery of signatures for higher (green line in graph) or lower (red line) survival rates would help doctors to manage the expectations of their patients. Survival predictions for cutaneous melanoma were originally based on clinical parameters: tumor location, Breslow thickness (how deep it spreads into the skin), stage (size and distance spread), and grade (how its cells look under the microscope). Advances in cancer genetics led to the discovery of biomarkers (such as the V600E mutation in the BRAF gene) that enabled more accurate predictions. Advances in transcriptomics also led to biomarkers, such as the level of transcription of a gene called MITF. Guo et al. complemented these approaches by analyzing epigenomics data to identify a biomarker based on DNA methylation marks (orange box): the predictive power of the new biomarkers is higher than that of previous biomarkers.
To continue the search for better biomarkers researchers went from studying genomics and transcriptomics to studying epigenomic changes such as DNA methylation (Figure 1). Multiple studies have shown that the addition of methyl group to certain DNA nucleotides plays important roles in tumor formation and cancer progression. Furthermore, these methyl markers are easily detectable and remain stable in biological samples, making them clinically useful as biomarkers (Keeley et al., 2013). Now, in eLife, Qiang Wang, Jian-Qun Chen and co-workers at Nanjing University and Shanghai University – including Wenna Guo and Liucun Zhu as joint first authors – report the discovery of a biomarker based on DNA methylation that provides the most accurate predictions of melanoma survival to date (Guo et al., 2019).
Guo et al. studied the methylation profile of 461 cutaneous melanoma patients from the Cancer Genome Atlas Project (International Cancer Genome Consortium et al., 2010). Regression analysis of this dataset revealed 4,454 DNA methylation sites that were associated with overall melanoma survival. Exploring all possible combinations of these markers identified a combination of four methylation marks that could optimally predict the survival of melanoma patients (Figure 1). Intriguingly, two out of the four methylation marks are in close proximity to two genes that are known to be associated with cutaneous melanoma: OCA2, which was found to be genetically varied in melanoma patients (Law et al., 2015), and RAB37, which is a member of an oncogene family.
Understanding the biological basis of the link between these methylation marks and survival will be challenging. DNA methylation could be controlling gene expression: however, the direction of this effect would need to be determined on gene by gene basis. Interestingly, Guo et al. also found that their four-methylation-mark signature has similarities to a signature used in cancer immunotherapy. The predictive power of the new biomarker is also higher than that of other biomarkers, including the five-DNA methylation signature that can predict the immune response to tumors (Jeschke et al., 2017).
Improvements in our ability to predict disease outcome are valuable in their own right. Moreover, a better understanding of the biology responsible for the correlations observed between the methylation signature, gene expression and immunotherapy targets has the potential to contribute to the global efforts to find a cure for melanoma.
References
-
Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancersMolecular Cancer Therapeutics 16:2598–2608.https://doi.org/10.1158/1535-7163.MCT-17-0386
-
Cutaneous melanoma: prognostic factorsCancer Control 12:223–229.https://doi.org/10.1177/107327480501200403
-
DNA methylation-based immune response signature improves patient diagnosis in multiple cancersJournal of Clinical Investigation 127:3090–3102.https://doi.org/10.1172/JCI91095
Article and author information
Author details
Publication history
Copyright
© 2019, Artomov
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,332
- views
-
- 114
- downloads
-
- 3
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Biomarkers: Improving survival prediction for melanoma
eLife 8:e48145.
https://doi.org/10.7554/eLife.48145
Further reading
-
- Cancer Biology
- Structural Biology and Molecular Biophysics
MET is a receptor tyrosine kinase (RTK) responsible for initiating signaling pathways involved in development and wound repair. MET activation relies on ligand binding to the extracellular receptor, which prompts dimerization, intracellular phosphorylation, and recruitment of associated signaling proteins. Mutations, which are predominantly observed clinically in the intracellular juxtamembrane and kinase domains, can disrupt typical MET regulatory mechanisms. Understanding how juxtamembrane variants, such as exon 14 skipping (METΔEx14), and rare kinase domain mutations can increase signaling, often leading to cancer, remains a challenge. Here, we perform a parallel deep mutational scan (DMS) of the MET intracellular kinase domain in two fusion protein backgrounds: wild-type and METΔEx14. Our comparative approach has revealed a critical hydrophobic interaction between a juxtamembrane segment and the kinase ⍺C-helix, pointing to potential differences in regulatory mechanisms between MET and other RTKs. Additionally, we have uncovered a β5 motif that acts as a structural pivot for the kinase domain in MET and other TAM family of kinases. We also describe a number of previously unknown activating mutations, aiding the effort to annotate driver, passenger, and drug resistance mutations in the MET kinase domain.
-
- Cancer Biology
Tumor neoantigen peptide vaccines hold potential for boosting cancer immunotherapy, yet efficiently co-delivering peptides and adjuvants to antigen-presenting cells in vivo remains challenging. Virus-like particle (VLP), which is a kind of multiprotein structure organized as virus, can deliver therapeutic substances into cells and stimulate immune response. However, the weak targeted delivery of VLP in vivo and its susceptibility to neutralization by antibodies hinder their clinical applications. Here, we first designed a novel protein carrier using the mammalian-derived capsid protein PEG10, which can self-assemble into endogenous VLP (eVLP) with high protein loading and transfection efficiency. Then, an engineered tumor vaccine, named ePAC, was developed by packaging genetically encoded neoantigen into eVLP with further modification of CpG-ODN on its surface to serve as an adjuvant and targeting unit to dendritic cells (DCs). Significantly, ePAC can efficiently target and transport neoantigens to DCs, and promote DCs maturation to induce neoantigen-specific T cells. Moreover, in mouse orthotopic liver cancer and humanized mouse tumor models, ePAC combined with anti-TIM-3 exhibited remarkable antitumor efficacy. Overall, these results support that ePAC could be safely utilized as cancer vaccines for antitumor therapy, showing significant potential for clinical translation.
